Mesalazine 1.2 TAKEDA (mesalazine) 1.2 g prolonged release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

mesalazine 1.2 takeda (mesalazine) 1.2 g prolonged release tablet blister pack

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

TachoSil sealant matrix European Union - English - myHealthbox

tachosil sealant matrix

takeda austria gmbh - human fibrinogen / human thrombin - sealant matrix - 5.5 mg human fibrinogen and 2.0 iu human thrombin per cm² - hemostasis, surgical - local haemostatics - indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient

ALUNBRIG 30 MG Israel - English - Ministry of Health

alunbrig 30 mg

takeda israel ltd - brigatinib - film coated tablets - brigatinib 30 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

ALUNBRIG 90 MG Israel - English - Ministry of Health

alunbrig 90 mg

takeda israel ltd - brigatinib - film coated tablets - brigatinib 90 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

HUMAN ALBUMIN TAKEDA 200 MGML SOLUTION FOR INFUSION Israel - English - Ministry of Health

human albumin takeda 200 mgml solution for infusion

takeda israel ltd - albumin human - solution for infusion - albumin human 200 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

HUMAN ALBUMIN TAKEDA 50 MGML SOLUTION FOR INFUSION Israel - English - Ministry of Health

human albumin takeda 50 mgml solution for infusion

takeda israel ltd - albumin human - solution for infusion - albumin human 50 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

DEXLANSOPRAZOLE TAKEDA 30 Milligram Capsules Modified Release Ireland - English - HPRA (Health Products Regulatory Authority)

dexlansoprazole takeda 30 milligram capsules modified release

takeda pharma a/s - dexlansoprazole - capsules modified release - 30 milligram

DEXLANSOPRAZOLE TAKEDA 60 Milligram Capsules Modified Release Ireland - English - HPRA (Health Products Regulatory Authority)

dexlansoprazole takeda 60 milligram capsules modified release

takeda pharma a/s - dexlansoprazole - capsules modified release - 60 milligram

DEXILANT 30 MG Israel - English - Ministry of Health

dexilant 30 mg

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

DEXILANT 60 MG Israel - English - Ministry of Health

dexilant 60 mg

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis